Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
暂无分享,去创建一个
H. Goldschmidt | E. Nievergall | T. Holderried | J. Dürig | C. Scheid | R. Schroers | R. Fenk | D. Tichy | K. Kriegsmann | S. Luntz | M. Munder | W. Knauf | C. Khandanpour | N. Weinhold | S. Huhn | U. Bertsch | H. Salwender | M. Raab | E. Mai | K. Weisel | J. Thomalla | M. Hoffmann | A. Asemissen | M. Hänel | T. Geer | B. Heilmeier | K. Trautmann-Grill | H. Riesenberg | D. Gezer | I. von Metzler | B. Besemer | C. Mann | M. Klaiber-Hakimi | M. Müller | I. von Metzler